Good News! The Company Selected for Chengdu’s 2023 New Economy Gradient Cultivation Enterprise List

Recently, the Office of the Chengdu New Economic Development Leading Group announced the Chengdu’s 2023 New Economy Gradient Cultivation Enterprise List. The list was compiled following a thorough process that included voluntary applications from enterprises, preliminary reviews by district and county authorities, expert evaluations, and verification by municipal departments. It includes categories such as New Economy Demonstration Enterprises, New Economy Double-Hundred Action Enterprises, and New Economy Seed Enterprises. Chengdu Shibeikang Biomedical Technology Co., Ltd. has been proudly selected for this prestigious list.

The Chengdu New Economy Gradient Cultivation Enterprises are chosen based on five key indicators: innovation capability, revenue scale, financing and valuation, talent team, and certifications. The list includes 30 “New Economy Demonstration Enterprises”, 100 “Economy Double-Hundred Action Enterprises” and 1,000 “New Economy Seed Enterprises”. The initiative is designed to provide tailored support, fostering a group of top-tier enterprises known for their outstanding products, strong brands, leading innovation, and modern governance.

Chengdu SBK is a high-tech enterprise dedicated to innovative drug R&D. Over recent years, the company has significantly ramped up its R&D investment, driven technological innovation, and made great strides in developing cutting-edge medicines. The number of authorized invention patents has steadily increased from 4 in 2020 to 28 today. Among the company’s key R&D achievements are the development of 14 drug varieties, including: 2 new drugs that have submitted DNA applications, 2 drugs that have completed clinical studies and are preparing to file NDAs, 1 drug that has completed Phase I clinical trials and is set to begin Phase II, and several others that are ready to enter clinical trials. Looking ahead, Chengdu SBK will stay true to its core mission, continue attracting top talent, and push forward with the R&D and transformation of innovative drugs. The company remains committed to delivering safer and more effective treatments for patients while also contributing to the economic growth of the region.